News & Events about Pliant Therapeutics Inc.
FVC Change from Baseline over 24 Weeks: ITT Population | ITT Population- SoC Subgroup
Figure 1. Change in FVC from Baseline of Bexotegrast 320 mg Over 24 Weeks
Figure 2.
Proportion of Patients with FVC Change from Baseline of Bexotegrast 320 mg Over 12 and 24 Weeks versus Placebo - Intent to ...
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliants President...
InvestorPlace
2 months ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.
The post 7 Biotech Stocks to Buy for 100% Returns appeared first on InvestorPlace...
Pliant Therapeutics, Inc. (NASDAQ:PLRX Get Rating) CFO Keith Lamont Cummings sold 9,960 shares of the stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $26.52, for a total value of $264,139.20. Following the sale, the chief financial officer now directly owns ...
Pliant Therapeutics, Inc. (NASDAQ:PLRX Get Rating) insider Eric Lefebvre sold 11,245 shares of Pliant Therapeutics stock in a transaction on Thursday, March 30th. The shares were sold at an average price of $26.52, for a total value of $298,217.40. Following the completion of the sale, the insider ...